Fontan术后蛋白丢失性肠病与塑性支气管炎的风险因素与结局
该研究基于澳大利亚新西兰Fontan注册队列1561例患者,回顾性分析Fontan术后蛋白丢失性肠病(PLE)与塑性支气管炎(PB)的风险因素及结局。独立预测因素包括右心室形态合并左心发育不良综合征、Fontan时年龄较大及术后胸腔积液,左心室形态具保护作用;诊断后5年死亡或移植率为30%。
要点
- 右心室形态合并左心发育不良综合征、Fontan时年龄大、术后胸腔积液增加PLE/PB风险。
- 左心室形态对PLE/PB发生具保护作用(HR 0.36)。
- PLE/PB诊断后5年无死亡或移植生存率为70%,仅较大年龄为不良预后独立预测因素。
核心结论
- Fontan术后PLE/PB仍是严重并发症,主要影响右优势型单心室患者,Fontan时年龄较大是发生及预后不良的预测因素。
研究设计与样本
- 回顾性分析澳大利亚新西兰Fontan注册队列1561例患者,采用Cox回归或累积发生率曲线及病因特异性回归分析死亡与心脏移植终点。
主要发现
- 共55例发生PLE/PB,Fontan中位年龄5.7岁,PLE发病距Fontan中位5.0年,PB中位1.7年。
- 20例患者接受26次外科干预,包括Fontan修正5例、开窗11例、Fontan转换5例、房室瓣修复3例、肝静脉改道2例。
临床怎么用
- 对右心室形态合并左心发育不良综合征、Fontan时年龄较大或术后胸腔积液患者应警惕PLE/PB发生。
- PLE/PB诊断后5年内约30%死亡或需移植,心脏移植仍是最终治疗,其余患者可长期稳定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Protein losing enteropathy and plastic bronchitis are severe complications in Fontan circulation, with 5-year survival ranging from 46% to 88%. We report risk factors and outcomes of protein losing enteropathy and plastic bronchitis in patients undergoing the Fontan. METHODS: We performed a retrospective analysis of 1561 patients from the Australia New Zealand Fontan Registry. Two end points were death and cardiac transplantation examined with Cox regression (if no competing risks) or cumulative incidence curves and cause-specific Cs regression. RESULTS: A total of 55 patients with protein losing enteropathy/plastic bronchitis were included. Their median age at the Fontan was 5.7 years, and time to onset after the Fontan for protein losing enteropathy was 5.0 years and plastic bronchitis was 1.7 years. Independent predictors for developing protein losing enteropathy/plastic bronchitis were right-ventricular morphology with hypoplastic left-heart syndrome (hazard ratio, 2.30; confidence interval, 1.12-4.74), older age at Fontan (hazard ratio, 1.13; confidence interval, 1.03-1.23), and pleural effusions after Fontan (hazard ratio, 2.43; confidence interval, 1.09-5.41); left-ventricular morphology was protective (hazard ratio, 0.36; confidence interval, 0.18-0.70). In the protein losing enteropathy/plastic bronchitis population, freedom from death or transplantation after protein losing enteropathy/plastic bronchitis diagnosis at 5, 10, and 15 years was 70% (confidence interval, 58-85), 65% (confidence interval, 51-83), and 43% (confidence interval, 26-73), respectively; only older age (hazard ratio, 1.23; confidence interval, 1.01-1.52) was an independent predictor. Twenty-six surgical interventions were performed in 20 patients, comprising Fontan revisions (n = 5), fenestrations (n = 11), Fontan conversions (n = 5), atrioventricular valve repairs (n = 3), and hepatic vein diversion (n = 2). CONCLUSIONS: Protein losing enteropathy and plastic bronchitis remain severe complications, preferably affecting patients with dominant right single ventricle, with older age at Fontan being a predictor of developing protein losing enteropathy/plastic bronchitis and poorer prognosis. Heart transplantation remains the ultimate treatment, with 30% dying or requiring transplantation within 5 years, and the remaining being stable for long periods.
引用
- Sharma VJ, Iyengar AJ, Zannino D, et al. Protein-losing enteropathy and plastic bronchitis after the Fontan procedure. J Thorac Cardiovasc Surg. 2020. PMID: 32928546. doi:10.1016/j.jtcvs.2020.07.107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。